Stock EW EDWARDS LIFESCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Market Closed - Nyse
Other stock markets
 16:00:02 2024-04-26 EDT 		5-day change 1st Jan Change
86.43 USD -1.80% Intraday chart for Edwards Lifesciences Corporation +0.57% +13.35%
04-26 Evercore ISI Adjusts Price Target on Edwards Lifesciences to $89 From $92 MT
04-26 Stifel Adjusts Price Target on Edwards Lifesciences to $85 From $83 MT

Evolution of the average Target Price on Edwards Lifesciences Corporation

Price target over the last 5 years

History of analyst recommendation changes

be53184cf37eda.DSnnkU_-9AJqT9rsrzGzRC7HUhEeav9mu9IMEzLaS5I.bhyi4QG9jVRdGZnZ7QDQdnylNV1BR8hR2YBiWFerEvtVRYnBd7qNZi92mw~fd77cdb394cb098b8915f6b39d01aa21

Analyst Recommendations on Edwards Lifesciences Corporation

Evercore ISI Adjusts Price Target on Edwards Lifesciences to $89 From $92 MT
Stifel Adjusts Price Target on Edwards Lifesciences to $85 From $83 MT
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $99 From $94 MT
UBS Adjusts Edwards Lifesciences Price Target to $95 From $92, Maintains Neutral Rating MT
Piper Sandler Adjusts Price Target on Edwards Lifesciences to $88 From $85 MT
Canaccord Genuity Trims Price Target on Edwards Lifesciences to $85 From $86 MT
Baird Adjusts Edwards Lifesciences Price Target to $102 From $100 MT
Leerink Partners Adjusts Edwards Lifesciences' Price Target to $93 From $96, Keeps Market Perform Rating MT
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca Our Logo
Zacks Investment Research Adjusts Price Target on Edwards Lifesciences to $95 From $97 MT
Truist Securities Adjusts Edwards Lifesciences Price Target to $105 From $97, Buy Rating Kept MT
RBC Raises Price Target on Edwards Lifesciences to $101 From $95, Keeps Outperform Rating MT
Mizuho Securities Adjusts Price Target on Edwards Lifesciences to $105 From $95, Maintains Buy Rating MT
Edwards Lifesciences Insider Sold Shares Worth $1,154,142, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $1,329,472, According to a Recent SEC Filing MT
Edwards Lifesciences Insider Sold Shares Worth $2,712,418, According to a Recent SEC Filing MT
Citigroup Raises Price Target on Edwards Lifesciences to $98 From $90, Maintains Neutral Rating MT
Edwards Lifesciences Insider Sold Shares Worth $688,423, According to a Recent SEC Filing MT
Morgan Stanley Lifts Price Target on Edwards Lifesciences to $103 From $95, Sees 'Upside Risk' Amid Transcatheter Mitral & Tricuspid Therapies, Overweight Rating Kept MT
Oppenheimer Raises Edwards Lifesciences Price Target to $100 From $93, Maintains Outperform Rating MT
BofA Securities Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $97 MT
UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating MT
Canaccord Genuity Adjusts Price Target on Edwards Lifesciences to $86 From $81, Maintains Hold Rating MT
Fed officials fail to convince investors, who are focused on earnings Our Logo
Oppenheimer Adjusts Edwards Lifesciences Price Target to $93 From $90, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.43 USD
Average target price
94.66 USD
Spread / Average Target
+9.52%
High Price Target
105 USD
Spread / Highest target
+21.49%
Low Price Target
72 USD
Spread / Lowest Target
-16.70%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Edwards Lifesciences Corporation

Evercore ISI
Stifel Nicolaus
Wells Fargo Securities
UBS
Piper Sandler
Canaccord Genuity
Baird
Leerink Partners
Zacks Investment Research
Truist Securities
RBC Capital Markets
Mizuho Securities
Citigroup
Morgan Stanley
Oppenheimer
BofA Securities
Jefferies & Co.
JPMorgan Chase
Wolfe Research
Deutsche Bank Securities
TD Cowen
Barclays
Bernstein
Raymond James
Goldman Sachs
Cowen
SVB Leerink
Credit Suisse
Atlantic Equities

Ratings for Edwards Lifesciences Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. EW Stock
  4. Consensus Edwards Lifesciences Corporation